Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 7/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2179974 | 0.86 | ESR1 (0.51) | ESR1ESR2APP | |
| SCHEMBL2182368 | 0.72 | ACHE (0.45) | CYP3A4ACHE | |
| SCHEMBL12413233 | 0.70 | LMNA (0.48) | CYP3A4CYP1A2CYP2C19ACHE | |
| SCHEMBL2183376 | 0.69 | ESR2 (0.44) | ESR1ESR2HSD17B1HSD17B2APP | |
| SCHEMBL2182963 | 0.69 | ESR1 (0.42) | ESR1ESR2APP | |
| SCHEMBL530039 | 0.68 | ESR1 (0.42) | ESR1ESR2APPCYP3A4 | |
| SCHEMBL237510 | 0.68 | TYR (0.43) | ESR1ESR2HSD17B1HSD17B2APP | |
| SCHEMBL13970430 | 0.68 | ESR2 (0.46) | ESR1ESR2HSD17B1HSD17B2APP | |
| SCHEMBL8288090 | 0.68 | ESR1 (0.40) | ESR1ESR2APP | |
| SCHEMBL2186431 | 0.68 | ESR2 (0.43) | ESR1ESR2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| WO-2009003229-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LTD (AU) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NFE2L2, PTGS2, PTGES2 | ESR1 90/4885ESR2 8/4885HSD17B1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.